Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina

被引：0
|
作者：
Victoria Wurcel
Diana Chirovsky
Rebekah Borse
Juan Ignacio Altuna
Fernando Carabajal
Jyotika Gandhi
机构：
[1] MSD Argentina,
[2] Merck & Co.,undefined
[3] Inc.,undefined
[4] CHEORS,undefined
来源：
Advances in Therapy | 2021年 / 38卷
关键词：
Argentina; Cetuximab; Cost-effectiveness; Head and neck squamous cell carcinoma; Latin America; Pembrolizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2613 / 2630
页数：17
相关论文
共 50 条
  • [1] Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina
    Wurcel, Victoria
    Chirovsky, Diana
    Borse, Rebekah
    Altuna, Juan Ignacio
    Carabajal, Fernando
    Gandhi, Jyotika
    ADVANCES IN THERAPY, 2021, 38 (05) : 2613 - 2630
  • [2] COST-EFFECTIVENESS OF PEMBROLIZUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA IN COLOMBIA
    Urrego-Reyes, J.
    Lopez, C.
    Marrugo, A. C.
    Wurcel, V
    Khandelwal, A.
    Patel, A.
    Black, C.
    VALUE IN HEALTH, 2023, 26 (06) : S95 - S95
  • [3] Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States
    Borse, Rebekah H.
    Ramakrishnan, Karthik
    Gandhi, Jyotika
    Dhankhar, Praveen
    Chirovsky, Diana
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 954 - 965
  • [4] Cost-effectiveness of pembrolizumab as monotherapy or in combination with chemotherapy versus EXTREME regimen for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in Taiwan
    Wang, C. H.
    Lei, H. L.
    Borse, R.
    Chirovsky, D.
    Chien, L.
    Tan, S. C.
    Spiteri, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S1349 - S1349
  • [5] Cost-effectiveness analysis of nivolumab compared to pembrolizumab in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck
    Yeh, Justin
    Guddati, Achuta Kumar
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (06): : 1821 - 1826
  • [6] REAL-WORLD USE OF PEMBROLIZUMAB COMBINATION REGIMENS IN FIRST-LINE RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
    Black, Christopher
    Wang, Liya
    Ramakrishnan, Karthik
    Goto, Daisuke
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A832 - A832
  • [7] Cost-effectiveness of cetuximab for the first-line treatment of squamous cell carcinoma of the head and neck (SCCHN) in Canada
    Sambrook, J.
    Levy, A. R.
    Johnston, K. M.
    Ricard, N. J.
    Bourgault, C.
    Donato, B. M.
    Sheehan, F. G.
    Hotte, S. J.
    Chasen, M. R.
    Briggs, A. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] CARBOPLATIN, PACLITAXEL AND PEMBROLIZUMAB FOR THE FIRST LINE TREATMENT OF RECURRENT AND/OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
    Valadez, Angelica
    Welsh, Madeleine
    Kim, Christine
    Johns, Angela
    Algazi, Alain
    Kang, Hyunseok
    Kang, Hyunseok
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A118 - A118
  • [9] Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma
    Zargar, Mahdi
    McFarlane, Thomas
    Chan, Kelvin K. W.
    Wong, William W. L.
    ONCOLOGIST, 2018, 23 (02): : 225 - 233
  • [10] Pembrolizumab vs the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis
    Yitian Lang
    Deshi Dong
    Bin Wu
    Clinical Drug Investigation, 2020, 40 : 1137 - 1146
12345